Journal of
eISSN: 2376-0060
Submit manuscript...
Editorial Volume 9 Issue 4
Community asymptomatic COVID-19 laboratory testing related hospital admission
Attapon Cheepsattayakorn,1,2 
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun1
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand
Received: December 15, 2022 | Published: December 30, 2022
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. Community asymptomatic COVID-19 laboratory testing related hospital admission. J Lung Pulm Respir Res. 2022;9(4):107. DOI: 10.15406/jlprr.2022.09.00290
Editorial
Hospital admission laboratory screening for asymptomatic COVID-19 has been used in COVID-19 pandemic management, particularly mitigation of the healthcare staff,1,2 whereas more than half of community-COVID-19 transmission may originate from asymptomatic persons.1 Trend for the average COVID-19 hospital admission rates in Liverpool, United Kingdom across the middle layer super output areas (MSOAs), a standard geographical units in England compared with a synthetic control group during October 5, 2020 and January 17, 2021, using Hospital Episode Statistics provided by the National Health Service (NHS) Digital System (average population of 7,200 individuals), as demonstrated hospital admissions was low in Liverpool than in the synthetic control group that continued throughout December 2020 then rising abruptly in January 2021 coincided with the expansion of the community COVID-19 testing in other areas and matched that of the synthetic control group (Figure 1).2 COVID-19-symptom-based testing has demonstrated to be not sensitive but specific.3,4 Variation of in incidence of asymptomatic COVID-19 ranged from 18 to 81 %5–7 due to different laboratory screening among countries’ policies.8
Figure 1 Demonstrating Trend in weekly covid-19 hospital admission rates in middle layer super output areas (MSOAs) in Liverpool city compared with a synthetic control group constructed from the weighted average of MSOAs outside Liverpool City Region without community testing. Community testing pilot for SARS-CoV-2 was introduced in Liverpool on 6 November 2020.2
In conclusion, at the hospital level, in those patients with any symptoms having low COVID-19 suspicion should be considered among the strategies of COVID-19 laboratory testing.
Acknowledgments
None.
Conflicts of interest
There are no conflicting interests declared by the authors.
Funding
None.
References
- Cihlar JL, Harris BD, Wright PW, et al. Universal admission laboratory screening for sever acute respiratory coronavirus 2 (SARS-CoV-2) asymptomatic infection across a large health system. Infect Control Hosp Epidemiol. 2022;1–7.
- Zhang X, Barr B, Green M, et al. Impact of community asymptomatic rapid antigen testing on COVID-19 related hospital admissions : synthetic control study. BMJ. 2022;379:e071374
- Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife. 2020;9:e58728.
- Requena Me´ndez A, Mougkou A, Hedberg P, et al. SARS-CoV-2 testing in patients with low COVID-19 suspicion at admission to a tertiary care hospital, Stockholm, Sweden, March to September 2020. Euro Surveill. 2022;27 (7):2100079.
- Nikolai LA, Meyer GC, Kremsner PG, et al. Asymptomatic SARS coronavirus 2 infection : invisible yet invicible. Int J Infect Dis. 2020;100:112–116.
- Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. Euro Surveill 2020;25(10):2000180.
- Cassini I, Navazzi F, Giardina F, et al. Performance of VivaDiag COVID-19 IgM/IgG rapid test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol. 2020;92 (10):1724–1727.
- Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12–16.
©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.
Citations
November is Lung Cancer Awareness Month, a vital opportunity for us to raise awareness about the dangers of lung cancer. Let’s unite to educate ourselves and others, and inspire proactive steps toward lung health. This year the motto of this event is “Stronger Together: United for Lung Cancer Awareness”. So for this occasion, the Journal of Lung, Pulmonary & Respiratory Research invites articles that emphasize the significance of lung protection. All the submissions received in the month of November will be offered with 40% discount on publication.